Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Preferred Stock Liabilities (2017 - 2021)

Cogent Biosciences has reported Preferred Stock Liabilities over the past 4 years, most recently at $85.4 million for Q3 2021.

  • Quarterly results put Preferred Stock Liabilities at $85.4 million for Q3 2021, down 38.22% from a year ago — trailing twelve months through Sep 2021 was $85.4 million (down 38.22% YoY), and the annual figure for FY2020 was $110.9 million, changed.
  • Preferred Stock Liabilities for Q3 2021 was $85.4 million at Cogent Biosciences, roughly flat from $85.4 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for COGT hit a ceiling of $138.2 million in Q3 2020 and a floor of $77.2 million in Q4 2017.
  • Median Preferred Stock Liabilities over the past 4 years was $85.4 million (2021), compared with a mean of $95.6 million.
  • Peak annual rise in Preferred Stock Liabilities hit 38.22% in 2021, while the deepest fall reached 38.22% in 2021.
  • Cogent Biosciences' Preferred Stock Liabilities stood at $77.2 million in 2017, then increased by 0.02% to $77.2 million in 2018, then skyrocketed by 43.69% to $110.9 million in 2020, then decreased by 22.98% to $85.4 million in 2021.
  • The last three reported values for Preferred Stock Liabilities were $85.4 million (Q3 2021), $85.4 million (Q2 2021), and $94.7 million (Q1 2021) per Business Quant data.